MedTrace Logo

Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel

NCT04110860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-01

No results posted yet for this study

Summary

Clinical study for the developed voriconazole self nano emulsifying drug delivery system intermediate gel was conducted on 30 patients with tinea versicolor infection.

Conditions

  • Tinea Versicolor

Interventions

DRUG

voriconazole gel once daily

voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily

DRUG

voriconazole gel twice daily

voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily

DRUG

placebo

the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner

Sponsors & Collaborators

  • Sara Botros

    lead OTHER

Principal Investigators

  • Sara R Botros, bachelor of clinical pharmacy · Minia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2018-06-20
Completion
2018-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110860 on ClinicalTrials.gov